Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

Blood

Volumn 126, Issue 24, 2015, Pages 2646-2649

  Freeman, Ciara L ^a   Morschhauser, Franck ^b   Sehn, Laurie ^c   Dixon, Mark ^d   Houghton, Richard ^d   Lamy, Thierry ^e   Fingerle Rowson, Günter ^f   Wassner Fritsch, Elisabeth ^f   Gribben, John G ^a   Hallek, Michael ^g   Salles, Gilles ^h   Cartron, Guillaume ⁱ  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g UNIVERSITY OF COLOGNE   (Germany)

^h UNIVERSITÉ LYON 1   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD20 ANTIGEN; CHLORAMBUCIL; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; OBINUTUZUMAB; RITUXIMAB; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; CYTOKINE; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER PATIENT; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG WITHDRAWAL; GENE EXPRESSION; HUMAN; INCIDENCE; INFUSION RELATED REACTION; LETTER; LEUKOPENIA; LYMPHOCYTE COUNT; MONOTHERAPY; NATURAL KILLER CELL; NEUTROPENIA; NEUTROPHIL COUNT; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; RISK FACTOR; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR VOLUME; B LYMPHOCYTE; CAPILLARY LEAK SYNDROME; CHEMICALLY INDUCED; DRUG EFFECTS; EDEMA; HYPOTENSION; HYPOXIA; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE DEPLETION; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SECRETION (PROCESS); STATISTICS AND NUMERICAL DATA; SYNDROME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CAPILLARY LEAK SYNDROME; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CYTOKINES; EDEMA; HUMANS; HYPOTENSION; HYPOXIA; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; INTERLEUKIN-8; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE DEPLETION; MULTICENTER STUDIES AS TOPIC; SYNDROME;

EID: 84951265456     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-670802     Document Type: Letter

References (24)

1. Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90(5):446-460.
2. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19(8):2153-2164.
3. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17(3):791-795.
4. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217-2224.
5. Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482-3491.
6. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402.
7. Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2011;152(3):295-306.
8. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-1110.
9. Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29(7):1602-1604.
10. Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012;119(22):5118-5125.
11. Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124(14):2196-2202.
12. Nyhlén K, Gautam C, Andersson R, Srinivas U. Modulation of cytokine-induced production of IL-8 in vitro by interferons and glucocorticosteroids. Inflammation. 2004;28(2):77-88.
13. Kara IO, Sahin B, Gunesacar R. Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis. Adv Ther. 2007;24(1):29-40.
14. Walz A, Meloni F, Clark-Lewis I, von Tscharner V, Baggiolini M. [Ca21]i changes and respiratory burst in human neutrophils and monocytes induced by NAP-1/interleukin-8, NAP-2, and gro/MGSA. J Leukoc Biol. 1991;50(3): 279-286.
15. Laprevotte E, Ysebaert L, Klein C, et al. Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. Leuk Res. 2013;37(4):440-446.
16. Krüttgen A, Rose-John S. Interleukin-6 in sepsis and capillary leakage syndrome. J Interferon Cytokine Res. 2012;32(2):60-65.
17. Gordon MS, Nemunaitis J, Hoffman R, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood. 1995;85(11):3066-3076.
18. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9(13):4653-4665.
19. Liu F, Jia L, Wang P, Farren T, Agrawal S. Tocilizumab overcomes chemo-resistance of CLL cells [abstract]. Blood. 2013;122(21). Abstract 5305.
20. Giezen TJ, Mantel-Teeuwisse AK, ten Berg MJ, et al. Rituximab-induced thrombocytopenia: a cohort study. Eur J Haematol. 2012;89(3):256-266.
21. Freeman CL, Dixon M, Houghton R, et al. Risk factors associated with the development of infusion-related reactions in patients with chronic lymphocytic leukaemia treated with anti-CD20 monoclonal antibodies: analysis of the CLL11 study dataset [abstract]. Blood. 2014;124(21). Abstract 3339.
22. Xia P, Gamble JR, Rye K-A, et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA. 1998;95(24):14196-14201.
23. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122(4):143-159.
24. Ram R, Bonstein L, Gafter-Gvili A, Ben-Bassat I, Shpilberg O, Raanani P. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. Am J Hematol. 2009;84(4):247-250.